Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9HBD1

UPID:
RC3H2_HUMAN

ALTERNATIVE NAMES:
Membrane-associated nucleic acid-binding protein; RING finger and CCCH-type zinc finger domain-containing protein 2; RING finger protein 164; RING-type E3 ubiquitin transferase Roquin-2

ALTERNATIVE UPACC:
Q9HBD1; Q4VXB1; Q5JPD7; Q86ST6; Q8N3D6; Q96F27; Q9H5J2; Q9HBD2; Q9NWN9; Q9NXE1

BACKGROUND:
The protein Roquin-2, with alternative names such as Membrane-associated nucleic acid-binding protein and RING-type E3 ubiquitin transferase Roquin-2, plays a significant role in the immune system and cellular homeostasis. It functions by binding to specific mRNA motifs to promote their degradation, a key mechanism in preventing spontaneous differentiation of T cells and controlling inflammatory responses. Roquin-2's activity as a ubiquitin E3 ligase, forming polyubiquitin chains, further underscores its critical role in protein regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Roquin-2 offers a promising pathway to identifying novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.